Atara Biotherapeutics (ATRA) Receivables - Net (2022 - 2025)
Atara Biotherapeutics (ATRA) has disclosed Receivables - Net for 4 consecutive years, with $1.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Receivables - Net rose 43.3% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2025, up 43.3%, and an annual FY2024 reading of $1.5 million, down 95.65% over the prior year.
- Receivables - Net was $1.9 million for Q3 2025 at Atara Biotherapeutics, down from $8.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $40.2 million in Q4 2022 and bottomed at $163000.0 in Q3 2023.
- Average Receivables - Net over 4 years is $9.2 million, with a median of $1.4 million recorded in 2024.
- Peak annual rise in Receivables - Net hit 8926.2% in 2024, while the deepest fall reached 95.65% in 2024.
- Year by year, Receivables - Net stood at $40.2 million in 2022, then fell by 15.2% to $34.1 million in 2023, then plummeted by 95.65% to $1.5 million in 2024, then rose by 29.08% to $1.9 million in 2025.
- Business Quant data shows Receivables - Net for ATRA at $1.9 million in Q3 2025, $8.9 million in Q1 2025, and $1.5 million in Q4 2024.